
The advent of digital twins is reshaping how clinical trials are conducted by allowing researchers to significantly enhance trial efficiency and effectiveness. Amidst soaring development costs for new drugs, which are compounded by the high likelihood of trial failures, this AI-driven technology offers a promising escape from both financial and procedural constraints. Innovators in the field are already demonstrating how